|
1
|
Li-Weber M: Targeting apoptosis pathways
in cancer by Chinese medicine. Cancer Lett. 332:304–312. 2013.
View Article : Google Scholar
|
|
2
|
Gupta SC, Kim JH, Prasad S and Aggarwal
BB: Regulation of survival, proliferation, invasion, angiogenesis,
and metastasis of tumor cells through modulation of inflammatory
pathways by nutraceuticals. Cancer Metastasis Rev. 29:405–434.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Banerjee K and Mandal M: Oxidative stress
triggered by naturally occurring flavone apigenin results in
senescence and chemotherapeutic effect in human colorectal cancer
cells. Redox Biol. 5:153–162. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chan LP, Chou TH, Ding HY, Chen PR, Chiang
FY, Kuo PL and Liang CH: Apigenin induces apoptosis via tumor
necrosis factor receptor- and Bcl-2-mediated pathway and enhances
susceptibility of head and neck squamous cell carcinoma to
5-fluorouracil and cisplatin. Biochim Biophys Acta. 1820:1081–1091.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kachadourian R and Day BJ:
Flavonoid-induced glutathione depletion: Potential implications for
cancer treatment. Free Radic Biol Med. 41:65–76. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shukla S and Gupta S: Apigenin-induced
prostate cancer cell death is initiated by reactive oxygen species
and p53 activation. Free Radic Biol Med. 44:1833–1845. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cairns RA, Harris IS and Mak TW:
Regulation of cancer cell metabolism. Nat Rev Cancer. 11:85–95.
2011. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Vander Heiden MG: Targeting cancer
metabolism: A therapeutic window opens. Nat Rev Drug Discov.
10:671–684. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Vazquez F, Lim JH, Chim H, Bhalla K,
Girnun G, Pierce K, Clish CB, Granter SR, Widlund HR, Spiegelman
BM, et al: PGC1α expression defines a subset of human melanoma
tumors with increased mitochondrial capacity and resistance to
oxidative stress. Cancer Cell. 23:287–301. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Szablewski L: Expression of glucose
transporters in cancers. Biochim Biophys Acta. 1835:164–169.
2013.
|
|
11
|
Kim MS, Kwon JY, Kang NJ, Lee KW and Lee
HJ: Phloretin induces apoptosis in H-Ras MCF10A human breast tumor
cells through the activation of p53 via JNK and p38
mitogen-activated protein kinase signaling. Ann NY Acad Sci.
1171:479–483. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu Y, Cao Y, Zhang W, Bergmeier S, Qian
Y, Akbar H, Colvin R, Ding J, Tong L, Wu S, et al: A small-molecule
inhibitor of glucose transporter 1 downregulates glycolysis,
induces cell-cycle arrest, and inhibits cancer cell growth in vitro
and in vivo. Mol Cancer Ther. 11:1672–1682. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wood TE, Dalili S, Simpson CD, Hurren R,
Mao X, Saiz FS, Gronda M, Eberhard Y, Minden MD, Bilan PJ, et al: A
novel inhibitor of glucose uptake sensitizes cells to FAS-induced
cell death. Mol Cancer Ther. 7:3546–3555. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hatanaka M: Transport of sugars in tumor
cell membranes. Biochim Biophys Acta. 355:77–104. 1974.PubMed/NCBI
|
|
15
|
Ulanovskaya OA, Cui J, Kron SJ and Kozmin
SA: A pairwise chemical genetic screen identifies new inhibitors of
glucose transport. Chem Biol. 18:222–230. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Patra KC and Hay N: The pentose phosphate
pathway and cancer. Trends Biochem Sci. 39:347–354. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Budihardjo II, Walker DL, Svingen PA,
Buckwalter CA, Desnoyers S, Eckdahl S, Shah GM, Poirier GG, Reid
JM, Ames MM, et al: 6-Aminonicotinamide sensitizes human tumor cell
lines to cisplatin. Clin Cancer Res. 4:117–130. 1998.PubMed/NCBI
|
|
18
|
Zhao Y, Butler EB and Tan M: Targeting
cellular metabolism to improve cancer therapeutics. Cell Death Dis.
4:e5322013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Seltzer MJ, Bennett BD, Joshi AD, Gao P,
Thomas AG, Ferraris DV, Tsukamoto T, Rojas CJ, Slusher BS,
Rabinowitz JD, et al: Inhibition of glutaminase preferentially
slows growth of glioma cells with mutant IDH1. Cancer Res.
70:8981–8987. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang JB, Erickson JW, Fuji R, Ramachandran
S, Gao P, Dinavahi R, Wilson KF, Ambrosio AL, Dias SM, Dang CV, et
al: Targeting mitochondrial glutaminase activity inhibits oncogenic
transformation. Cancer Cell. 18:207–219. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lim JH, Luo C, Vazquez F and Puigserver P:
Targeting mitochondrial oxidative metabolism in melanoma causes
metabolic compensation through glucose and glutamine utilization.
Cancer Res. 74:3535–3545. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bao YY, Zhou SH, Fan J and Wang QY:
Anticancer mechanism of apigenin and the implications of GLUT-1
expression in head and neck cancers. Future Oncol. 9:1353–1364.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bao YY, Zhou SH, Lu ZJ, Fan J and Huang
YP: Inhibiting GLUT-1 expression and PI3K/Akt signaling using
apigenin improves the radiosensitivity of laryngeal carcinoma in
vivo. Oncol Rep. 34:1805–1814. 2015.PubMed/NCBI
|
|
24
|
Melstrom LG, Salabat MR, Ding XZ, Milam
BM, Strouch M, Pelling JC and Bentrem DJ: Apigenin inhibits the
GLUT-1 glucose transporter and the phosphoinositide 3-kinase/Akt
pathway in human pancreatic cancer cells. Pancreas. 37:426–431.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Xu YY, Wu TT, Zhou SH, Bao YY, Wang QY,
Fan J and Huang YP: Apigenin suppresses GLUT-1 and p-AKT expression
to enhance the chemosensitivity to cisplatin of laryngeal carcinoma
Hep-2 cells: An in vitro study. Int J Clin Exp Pathol. 7:3938–3947.
2014.PubMed/NCBI
|
|
26
|
Hamanaka RB and Chandel NS: Targeting
glucose metabolism for cancer therapy. J Exp Med. 209:211–215.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jeon SM, Chandel NS and Hay N: AMPK
regulates NADPH homeostasis to promote tumour cell survival during
energy stress. Nature. 485:661–665. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lim JH: Zinc finger and BTB
domain-containing protein 3 is essential for the growth of cancer
cells. BMB Rep. 47:405–410. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Weinberg F, Hamanaka R, Wheaton WW,
Weinberg S, Joseph J, Lopez M, Kalyanaraman B, Mutlu GM, Budinger
GR and Chandel NS: Mitochondrial metabolism and ROS generation are
essential for Kras-mediated tumorigenicity. Proc Natl Acad Sci USA.
107:8788–8793. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Le A, Lane AN, Hamaker M, Bose S, Gouw A,
Barbi J, Tsukamoto T, Rojas CJ, Slusher BS, Zhang H, et al:
Glucose-independent glutamine metabolism via TCA cycling for
proliferation and survival in B cells. Cell Metab. 15:110–121.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wise DR and Thompson CB: Glutamine
addiction: A new therapeutic target in cancer. Trends Biochem Sci.
35:427–433. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Agullo G, Gamet-Payrastre L, Manenti S,
Viala C, Rémésy C, Chap H and Payrastre B: Relationship between
flavonoid structure and inhibition of phosphatidylinositol
3-kinase: A comparison with tyrosine kinase and protein kinase C
inhibition. Biochem Pharmacol. 53:1649–1657. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Fang J, Xia C, Cao Z, Zheng JZ, Reed E and
Jiang BH: Apigenin inhibits VEGF and HIF-1 expression via
PI3K/AKT/p70S6K1 and HDM2/p53 pathways. FASEB J. 19:342–353. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Huang YT, Kuo ML, Liu JY, Huang SY and Lin
JK: Inhibitions of protein kinase C and proto-oncogene expressions
in NIH 3T3 cells by apigenin. Eur J Cancer. 32A:146–151. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Llorens F, Miró FA, Casañas A, Roher N,
Garcia L, Plana M, Gómez N and Itarte E: Unbalanced activation of
ERK1/2 and MEK1/2 in apigenin-induced HeLa cell death. Exp Cell
Res. 299:15–26. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yin F, Giuliano AE, Law RE and Van Herle
AJ: Apigenin inhibits growth and induces G2/M arrest by modulating
cyclin-CDK regulators and ERK MAP kinase activation in breast
carcinoma cells. Anticancer Res. 21(1A): 413–420. 2001.PubMed/NCBI
|
|
37
|
Adekola K, Rosen ST and Shanmugam M:
Glucose transporters in cancer metabolism. Curr Opin Oncol.
24:650–654. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Gross MI, Demo SD, Dennison JB, Chen L,
Chernov-Rogan T, Goyal B, Janes JR, Laidig GJ, Lewis ER, Li J, et
al: Antitumor activity of the glutaminase inhibitor CB-839 in
triple-negative breast cancer. Mol Cancer Ther. 13:890–901. 2014.
View Article : Google Scholar : PubMed/NCBI
|
